HIGHLIGHTS
- who: Giuseppe Viscardi and collaborators from the Via Leonardo Bianchi, Naples, Italy have published the research work: Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review, in the Journal: (JOURNAL)
- what: In this study, PD-L1 expression was assessed using the SP263 immunohistochemistry (IHC) assay.
- future: Of course further investigations are needed to understand the biological and immunological mechanisms governing the differential efficacy of neoadjuvant 4 of 17 and adjuvant immunotherapy. Future research efforts will focus on minimal residual disease (MRD) to prioritize patient groups most likely to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.